Abstract
Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Current Pharmaceutical Design
Title: Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations
Volume: 9 Issue: 10
Author(s): William A. Banks
Affiliation:
Keywords: leptin,, obesity,, blood-brain barrier,, cerebrospinal fluid,, resistance,, transport
Abstract: Leptin has emerged as a major regulator of body adiposity. The majority of humans with obesity have a resistance to leptin. Human and rodent studies indicate that the major cause of this resistance arises from an impaired ability of leptin to cross the blood-brain barrier, with lesser roles played by receptor and post-receptor defects. Evidence from baboons living in the wild is consistent with the hypothesis that during most of evolution serum levels of leptin were much lower than those currently considered normal. Leptin may have evolved to signal to the brain when caloric reserves were adequate to engage in reproductive and other behaviors not immediately concerned with acquisition of calories. The leptin transporter is a regulated system, with the rate of transport being increased by alpha-1 adrenergic agents and decreased by starvation. Impaired regulation of the transporter or impairments in transporter production could underlie the resistance caused by transporter defects. Evolutionary pressures would not have selected against such impairments if leptin levels were lower than those typically seen in Western society. A model that could explain how leptin transporter resistance can be acquired is presented.
Export Options
About this article
Cite this article as:
Banks A. William, Is Obesity a Disease of the Blood-Brain Barrier? Physiological, Pathological, and Evolutionary Considerations, Current Pharmaceutical Design 2003; 9 (10) . https://dx.doi.org/10.2174/1381612033455350
DOI https://dx.doi.org/10.2174/1381612033455350 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Key Points in Management for Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
Current Drug Safety Mucoadhesive Nanoparticulate System for Oral Drug Delivery: A Review
Current Drug Therapy Bone Marrow Reconstitution as a Relevant Model of Genetically Programmed Leukemia
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Effect of TRAF1 on Phenotypic Changes Of Kupffer Cells In Liver Transplantation Ischemic-Reperfusion
Current Pharmaceutical Biotechnology A Review on Leukemia and iPSC Technology: Application in Novel Treatment and Future
Current Stem Cell Research & Therapy Pathophysiological and Clinical Aspects of Iron Chelation Therapy in MDS
Current Pharmaceutical Design Review in Quantitative Structure Activity Relationships on Lipoxygenase Inhibitors
Mini-Reviews in Medicinal Chemistry Leukocyte Function-Associated Antigen-1: Structure, Function and Application Prospects
Protein & Peptide Letters Neurotransmitters and Neuropeptides Expression in the Uterine Scar After Cesarean Section
Current Protein & Peptide Science Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity
Current Medicinal Chemistry Colorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Current Pharmaceutical Design A Neutralization scFv Antibody against IL-1β Isolated from a NIPA-based Bacterial Display Library
Current Pharmaceutical Biotechnology Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Role of Fractalkine (CX3CL1) in Regulating Neuron-Microglia Interactions: Development of Viral-Based CX3CR1 Antagonists
Current Alzheimer Research A Novel Monocyte-based Pyrogen Test Based on the Mechanism of Human Fever Reaction
Current Pharmaceutical Analysis Bioactive Principles and Potentiality of Hot Methanolic Extract of the Leaves from <i>Artemisia absinthium</i> L “<i>in vitro</i> Cytotoxicity Against Human MCF-7 Breast Cancer Cells, Antibacterial Study and Wound Healing Activity”
Current Pharmaceutical Biotechnology The Temporal Relationship between Pain Intensity and Pain Interference and Incident Dementia
Current Alzheimer Research Gene Variants and Haplotypes Modifying Transcription Factor Binding Sites in the Human Cyclooxygenase 1 and 2 (PTGS1 and PTGS2) Genes
Current Drug Metabolism Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology